Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (68)	3/8/1998 10:26:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 359

ABSC has extraordinarily capable scientific talent leading the company and has accumulated exclusive licenses on several fluorescence-based technologies through Dr. Roger Tsien that are particularly appropriate for HTS. Part of the name of the game is THROUGHPUT and ABSC is working on detection in a 3456-well format, whereas most other companies are now using 96-well or 384-well microplates. Although there are risks of success or failure of this technological leap, IMHO, it appears that ABSC is the best equipped company both technically and financially to overcome these, including developing the robotic handling and informatics. ALSO, ABSC seems to be developing a different position with companies in developing assays, an integrated package and future revenue streams than other HTS organizations. IMO, the stock price of ABSC may not take off until more insiders have sold some more of their holdings but it is also not likely to descend below its IPO price of about $10. I don't know who bought about 500,000 shares late in the day on Thursday at about 11 1/4 but the current momentum appears to be up again. The company has only about 17,000,000 shares out but a published float of only about 4,000,000 so 500,000 shares represents a significant portion of the stock traded in a single day.